AngioDynamics, Inc.’s ANGO investors have been experiencing some short-term losses from the stock of late. Shares of the Latham, NY-based medical technology company have plunged 13.8% in the past ...

AngioDynamics stock reacted positively to fiscal Q4 results, up over 25% in a day, as the company saw 8% sequential revenue growth and 14% growth from the Med Tech portfolio. Auryon and NanoKnife ...

AngioDynamics, Inc. ANGO is well-poised for growth in the coming quarters, courtesy of its potential in NanoKnife System. The positive outlook for the stock is driven by NanoKnife's strong performance ...

AngioDynamics' fiscal Q2'25 results exceeded expectations, with Med Tech growing 25% and delivering better gross margins, boosting confidence in achieving high single-digit revenue growth and ...

AngioDynamics beat on sales and beat on earnings this morning -- sort of. The company reported a smaller-than-expected adjusted loss, but its GAAP loss was much bigger. AngioDynamics lost money in ...

AngioDynamics reported mixed fiscal 2025 Q1 results. The medical technology company has had some good news recently, though. AngioDynamics continues to expect modest growth for the full year.

AngioDynamics, Inc. ANGO reported an adjusted loss per share of 4 cents for second-quarter fiscal 2025, narrower than the year-ago quarter’s adjusted loss per share of 5 cents and the Zacks Consensus ...

The medical technology company announced the retirement of CEO Jim Clemmer. This news creates uncertainty for AngioDynamics -- and investors dislike uncertainty. However, the company's business ...